Sirolimus or Everolimus Improves Survival After Liver Transplantation for Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis

The effects of mammalian target of rapamycin (mTOR) inhibitors (sirolimus [SRL] and everolimus [EVL]) on survival in liver transplantation (LT) recipients with hepatocellular carcinoma (HCC) remain the subject of intense research. Therefore, we performed this systematic review and meta‐analysis to i...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Liver transplantation 2022-06, Vol.28 (6), p.1063-1077
Hauptverfasser:	Yan, Xiangyu, Huang, Songhan, Yang, Yang, Lu, Ziwen, Li, Feiyu, Jiang, Liyong, Jiang, Yong, Liu, Jun
Format:	Artikel
Sprache:	eng
Schlagworte:	Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - surgery Clinical trials Everolimus - adverse effects Hepatocellular carcinoma Humans Immunosuppression Immunosuppressive Agents - adverse effects Liver cancer Liver Neoplasms - drug therapy Liver Neoplasms - surgery Liver transplantation Liver Transplantation - adverse effects Liver transplants Meta-analysis Rapamycin Risk assessment Sensitivity analysis Sirolimus - adverse effects Survival Systematic review Targeted cancer therapy TOR protein Toxicity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!